Stocks making the biggest moves after hours: Adobe, RH, Oracle and more [CNBC]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: CNBC
Adobe issued a fiscal fourth-quarter revenue forecast in a range between $5.50 billion to $5.55 billion. Analysts polled by LSEG had estimated $5.61 billion in revenue. Guidance for adjusted earnings per share came in at $4.63 to $4.68 per share, while analysts had expected $4.67 per share. Meanwhile, third-quarter adjusted earnings and revenue beat estimates. Oracle — The cloud software company advanced nearly 6% after raising its revenue guidance. The company announced during its analyst day on Thursday that it estimates 2026 revenue of at least $66 billion, higher than prior guidance for $65 billion and analysts' forecast for $64.8 billion, per FactSet. Neurocrine Biosciences — The neuroscience-focused biopharma company lost more than 2%. Neurocrine Biosciences reported that its investigational drug luvadaxistat, a schizophrenia treatment, failed to reach primary endpoints in a phase 2 study. RH — The home furnishings company surged nearly 19% after posting a top- and bottom-
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
- Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaPR Newswire
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferencePR Newswire
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Barclays PLC from $180.00 to $160.00. They now have an "overweight" rating on the stock.MarketBeat
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 9/17/24 - Form 4
- 9/13/24 - Form 144
- 8/28/24 - Form 8-K
- NBIX's page on the SEC website